Could Biomarkers of Bone, Cartilage or Synovium Turnover Be Used for Relapse Prediction in Rheumatoid Arthritis Patients?

Objective. The aim of this review is to clarify the usefulness of bone, cartilage, and synovial biomarker in the management of rheumatoid arthritis (RA) therapy in remission. Synovial Biomarkers. High MMP-3 levels are associated with joint progression in RA patients, but there is no data about their...

Full description

Saved in:
Bibliographic Details
Main Authors: Delphine Dénarié, Elodie Constant, Thierry Thomas, Hubert Marotte
Format: Article
Language:English
Published: Wiley 2014-01-01
Series:Mediators of Inflammation
Online Access:http://dx.doi.org/10.1155/2014/537324
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832559113640345600
author Delphine Dénarié
Elodie Constant
Thierry Thomas
Hubert Marotte
author_facet Delphine Dénarié
Elodie Constant
Thierry Thomas
Hubert Marotte
author_sort Delphine Dénarié
collection DOAJ
description Objective. The aim of this review is to clarify the usefulness of bone, cartilage, and synovial biomarker in the management of rheumatoid arthritis (RA) therapy in remission. Synovial Biomarkers. High MMP-3 levels are associated with joint progression in RA patients, but there is no data about their utility in clinical remission. IIINys and Glc-Gal-PYD seem to be more specific to synovium, but more studies are required. Cartilage Biomarkers. Unbalance between cartilage break-down biomarkers (urinary CTX II and COMP) and cartilage formation biomarker (PIIANP) was described. This unbalance is also associated with joint destruction and prognosis of destruction. No data are available on patients in remission. Bone Biomarkers. RA activity is correlated with an increase of bone resorption markers such as CTX I, PYD, and TRACP 5b and a decrease of bone formation markers such as OC and BALP. RA therapies seem to improve bone turnover in limiting bone resorption. There is no study about bone marker utility in remission. Conclusion. Biomarkers seem to correlate with RA activity and progression. They also could be used to manage RA therapies, but we need more data on RA remission to predict relapse.
format Article
id doaj-art-f7dc057096f04ee9b8e69510d95a61c4
institution Kabale University
issn 0962-9351
1466-1861
language English
publishDate 2014-01-01
publisher Wiley
record_format Article
series Mediators of Inflammation
spelling doaj-art-f7dc057096f04ee9b8e69510d95a61c42025-02-03T01:30:52ZengWileyMediators of Inflammation0962-93511466-18612014-01-01201410.1155/2014/537324537324Could Biomarkers of Bone, Cartilage or Synovium Turnover Be Used for Relapse Prediction in Rheumatoid Arthritis Patients?Delphine Dénarié0Elodie Constant1Thierry Thomas2Hubert Marotte3Department of Rheumatology, University Hospital Saint-Etienne, 42055 Saint-Etienne Cedex, FranceDepartment of Rheumatology, University Hospital Saint-Etienne, 42055 Saint-Etienne Cedex, FranceDepartment of Rheumatology, University Hospital Saint-Etienne, 42055 Saint-Etienne Cedex, FranceDepartment of Rheumatology, University Hospital Saint-Etienne, 42055 Saint-Etienne Cedex, FranceObjective. The aim of this review is to clarify the usefulness of bone, cartilage, and synovial biomarker in the management of rheumatoid arthritis (RA) therapy in remission. Synovial Biomarkers. High MMP-3 levels are associated with joint progression in RA patients, but there is no data about their utility in clinical remission. IIINys and Glc-Gal-PYD seem to be more specific to synovium, but more studies are required. Cartilage Biomarkers. Unbalance between cartilage break-down biomarkers (urinary CTX II and COMP) and cartilage formation biomarker (PIIANP) was described. This unbalance is also associated with joint destruction and prognosis of destruction. No data are available on patients in remission. Bone Biomarkers. RA activity is correlated with an increase of bone resorption markers such as CTX I, PYD, and TRACP 5b and a decrease of bone formation markers such as OC and BALP. RA therapies seem to improve bone turnover in limiting bone resorption. There is no study about bone marker utility in remission. Conclusion. Biomarkers seem to correlate with RA activity and progression. They also could be used to manage RA therapies, but we need more data on RA remission to predict relapse.http://dx.doi.org/10.1155/2014/537324
spellingShingle Delphine Dénarié
Elodie Constant
Thierry Thomas
Hubert Marotte
Could Biomarkers of Bone, Cartilage or Synovium Turnover Be Used for Relapse Prediction in Rheumatoid Arthritis Patients?
Mediators of Inflammation
title Could Biomarkers of Bone, Cartilage or Synovium Turnover Be Used for Relapse Prediction in Rheumatoid Arthritis Patients?
title_full Could Biomarkers of Bone, Cartilage or Synovium Turnover Be Used for Relapse Prediction in Rheumatoid Arthritis Patients?
title_fullStr Could Biomarkers of Bone, Cartilage or Synovium Turnover Be Used for Relapse Prediction in Rheumatoid Arthritis Patients?
title_full_unstemmed Could Biomarkers of Bone, Cartilage or Synovium Turnover Be Used for Relapse Prediction in Rheumatoid Arthritis Patients?
title_short Could Biomarkers of Bone, Cartilage or Synovium Turnover Be Used for Relapse Prediction in Rheumatoid Arthritis Patients?
title_sort could biomarkers of bone cartilage or synovium turnover be used for relapse prediction in rheumatoid arthritis patients
url http://dx.doi.org/10.1155/2014/537324
work_keys_str_mv AT delphinedenarie couldbiomarkersofbonecartilageorsynoviumturnoverbeusedforrelapsepredictioninrheumatoidarthritispatients
AT elodieconstant couldbiomarkersofbonecartilageorsynoviumturnoverbeusedforrelapsepredictioninrheumatoidarthritispatients
AT thierrythomas couldbiomarkersofbonecartilageorsynoviumturnoverbeusedforrelapsepredictioninrheumatoidarthritispatients
AT hubertmarotte couldbiomarkersofbonecartilageorsynoviumturnoverbeusedforrelapsepredictioninrheumatoidarthritispatients